Course of Hyperkalemia in Patients on Hemodialysis
Table 3
Dialysis adequacy and prescription parameters in placebo patients (n = 86).
Day
spKt/V
Urea removal rate (%)
Dialysate flow (mL/min)
Dialysate potassium concentration (mmol/L)
Prescribed ultrafiltration rate (mL)
Blood flow (mL/min)
−7
1.71 (0.38)
74.3 (5.8)
548.0 (131.1)
2.24 (0.46)
2785.8 (1228.1)
321.0 (95.8)
1
1.99 (0.85)
73.3 (6.4)
545.3 (133.7)
2.23 (0.48)
2753.0 (1197.1)
316.0 (95.8)
3
—
—
—
2.24 (0.48)
—
—
5
—
—
—
2.23 (0.48)
—
—
8
—
—
—
2.22 (0.47)
—
—
12
—
—
—
2.22 (0.47)
—
—
15
—
—
—
2.24 (0.48)
—
—
22
—
—
—
2.26 (0.57)
—
—
29
1.67 (0.35)
72.3 (7.1)
545.9 (143.3)
2.21 (0.47)
2807.6 (1176.5)
317.3 (95.0)
36
—
—
—
2.22 (0.47)
—
—
43
—
—
—
2.22 (0.48)
—
—
50
—
—
—
2.22 (0.48)
—
—
57
1.70 (0.43)
73.6 (5.4)
548.7 (130.4)
2.24 (0.46)
2843.0 (1098.3)
320.7 (98.8)
Data are mean (standard deviation). Data are shown for the 86 placebo patients with predialysis sK+ measurements at randomization (visit 4, day 1). sK+, serum potassium; spKt/V, target single pool Kt/V.